Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 679 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $16.00, for a total transaction of $10,864.00. Following the completion of the sale, the insider owned 3,622 shares in the company, valued at $57,952. This represents a 15.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, March 16th, Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80.

Avalo Therapeutics Price Performance

NASDAQ AVTX opened at $17.76 on Friday. The business’s fifty day moving average price is $15.54 and its 200-day moving average price is $15.96. The stock has a market capitalization of $404.75 million, a price-to-earnings ratio of -3.10 and a beta of 0.93. Avalo Therapeutics, Inc. has a 1-year low of $3.39 and a 1-year high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of ($0.21) million. Equities research analysts anticipate that Avalo Therapeutics, Inc. will post -19.07 EPS for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

Several large investors have recently made changes to their positions in AVTX. BIT Capital GmbH bought a new position in shares of Avalo Therapeutics in the third quarter worth about $25,000. PFS Partners LLC raised its stake in Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares during the period. Quadrature Capital Ltd purchased a new position in Avalo Therapeutics in the 2nd quarter worth approximately $55,000. Dimensional Fund Advisors LP purchased a new position in Avalo Therapeutics in the 3rd quarter worth approximately $143,000. Finally, Boothbay Fund Management LLC bought a new position in Avalo Therapeutics in the 2nd quarter worth approximately $56,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on AVTX shares. BTIG Research restated a “buy” rating and set a $40.00 price target on shares of Avalo Therapeutics in a research note on Tuesday, March 24th. HC Wainwright raised their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Guggenheim began coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Avalo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $42.25.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.